Page 74 - MEMORIA ANUAL 2021

MEMORIA ANUAL 2021 SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
PETHEMA
FUNDACIÓN ESPAÑOLA DE HEMATOLOGÍA Y HEMOTERAPIA
Puig N, Contreras Sanfeliciano T, Paiva B, Cedena MT, Rosiñol L, García-Sanz R, Martínez- López J, Oriol A, Blanchard MJ, Ríos R, Martín J, Sureda A, Hernández M, De La Rubia J, Krsnik I, Moraleda JM, Íñigo B, Palomera L, Agulló C, Bargay J, Bladé Creixenti J, San- Miguel J, Lahuerta JJ, Mateos MV .
• Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexameth- asone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with New- ly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial.
63rd Annual Meeting of the American-Society-of-Hematology (ASH). Georgia, Dec 11-14, 2021.
Rosiñol L, Oriol A, Ríos Tamayo R, Blanchard MJ, Jarque I, Bargay J, Hernández MT, Mora- leda JM, Carrillo-Cruz E, Sureda A, Martínez-López J, Krsnik I, González García E, Casado F, Martí JM, Encinas C, De Arriba F, Palomera L, Sampol A, González-Montes Y, Cabezudo E, Mateos MV, San-Miguel J, Lahuerta JJ, Bladé Creixenti J .
• Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies.
63rd Annual Meeting of the American-Society-of-Hematology (ASH). Georgia, Dec 11-14, 2021.
Burgos L, Tamariz-Amador LE, Puig N, Cedena MT, Jelinek T, Johnson SK, Milani P, Cordón L, Pérez JJ, Lasa M, Termini R, Oriol A, Hernández MT, Palomera L, Martínez Martínez R, de la Rubia J, De Arriba F, Ríos R, González ME, Gironella M, Cabañas V, Casanova M, Krsnik I, Pérez A, González De La Calle V, Rodríguez-Otero P, Maisnar V, Hajek R, van Rhee F, Jiménez-Zepeda VH, Palladini G, Milani P, Orfao A, Rosiñol L, Bladé Creixenti J, Martínez- López J, Lahuerta JJ, Mateos MV, San-Miguel JF, Paiva B .
• Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints.
63rd Annual Meeting of the American-Society-of-Hematology (ASH). Georgia, Dec 11-14, 2021.
Garcés JJ, Puig N, Termini R, Cedena MT, Moreno C, Pérez JJ, Alignani D, Sarai S, Oriol A, González García E, Escalante F, Sureda A, De Arriba F, Ríos R, Moraleda JM, Gironella M, Hernández MT, Bargay J, Palomera L, Orfao A, Terpos E, Pérez A, Jelinek T, Suárez A, Goldschmidt H, Avet-Loiseau H, Roccaro AM, Martínez-López J, Lahuerta JJ, Ocio E, Rosiñol L, Bladé Creixenti J, Mateos MV, San-Miguel J, Paiva B .
• Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study.
Clinical Lymphoma Myeloma & Leukemia. 2021;21:S22-S3.
74